Archive · 31 May 2025
FDA Approves New Moderna COVID-19 Vaccine, mNEXSPIKE
The FDA has given the okay to a new COVID-19 vaccine made by Moderna called mNEXSPIKE.
It's for people who are 65 or older, and those aged 12-64 who have health issues that make them more likely to get very sick from COVID-19.
This vaccine is for those who have already had a previous COVID-19 shot.
It's like an extra layer of defense.
If you've had a bad reaction to a previous COVID-19 vaccine, you shouldn't get this one.
Possible side effects can happen like trouble breathing and a fast heartbeat.
Moderna hopes it will be ready for use in the U.S. starting in 2025.
The FDA has approved Moderna's new COVID-19 vaccine, mNEXSPIKE.
It is approved for adults 65 and older, and individuals aged 12-64 with underlying risk factors.
The vaccine is designed for individuals who have already received a previous COVID-19 shot.
Moderna expects the vaccine to be available in the U.S. for the 2025-2026 respiratory virus season.
Side effects may include trouble breathing, swelling, fast heartbeat, rashes, dizziness and weakness.
- Who
- The vaccine is for adults 65 and older, and individuals aged 12-64 with underlying risk factors.
- What
- The FDA approved Moderna's mNEXSPIKE, a new COVID-19 vaccine.
- When
- Approved recently, expected to be available for the 2025-2026 respiratory virus season.
- Where
- U.S.
- Why
- To provide additional protection against COVID-19 for those at high risk of severe illness.
- Vaccine Name
- mNEXSPIKE
- Manufacturer
- Moderna
- Approval Agency
- U.S. FDA
- Target Groups
- Adults 65+, Individuals 12-64 with risk factors
- Intended Use
- Boosters for previously vaccinated
- Anticipated Availability
- 2025-2026 respiratory virus season
- Reported Deaths in 2024
- 47,000 Americans